An antibody fragment capable of modulating multidrug resistance (Technion)
- Summary
- The present invention relates to an antibody fragment capable of binding to P-glycoprotein associated with multidrug resistant (MDR) cells. The present invention also relates to compositions and methods utilizing such an antibody fragment for inhibiting drug efflux activity in MDR cancer cells.
Cancer chemotherapy often fails due to the development of acquired or intrinsic resistance in cancerous cells to a wide variety of anticancer drugs, such as colchicine, vinblastine, vincristine and doxorubicin. This phenomenon, which is known as multidrug resistance (MDR), is a major barrier to cancer chemotherapy.
A key mechanism of MDR is the overexpression of an energy-dependant efflux pump, known as the multidrug transporter. This efflux pump is a 170 kDa P-glycoprotein (Pgp), encoded by the MDR1 gene. Pgp-mediated MDR plays an important role in the resistance of various tumor cells to chemotherapy; studies have shown a clear correlation between mdr1 expression and the lack of response to chemotherapy.
The present invention demonstrates an antibody selectively reacts with Pgp-overexpressing cells and is therefore an effective inhibitor of drug-efflux activity in multi-drug resistant cells.
- ID No.
- DRS-0655
- Country/Region
- Israel
For more information, please click Here
